Építés alatt – nem éles oldal
Belépés
Résztvevőt keres itt: Egyesült Államok4. fázis

Strategic Help With Immunoglobulin to Enhance Protect Against Late Disease (CMV)

A legfontosabb adatok

Ki végzi
Camille N. Kotton, MD
Hol
Boston és Dallas (Egyesült Államok)Mind a 2 helyszín megnézése
Azonosító
Állapot
Toboroz
Fázis
4. fázis
Résztvevők
80 fő, tervezett
Kezdés
2025. nov. 27.
Várható befejezés
2028. máj. 31.
A vizsgálat típusa
Beavatkozással járó, 2 csoportAz egyik csoport nem kap vizsgálati kezelést, összehasonlításként.
A vizsgált kezelések
  • Cytomegalovirus Immune Globulin Intravenous (Human) monthly for three months
A regiszteradat frissítve
2025. december 22.

Ki vehet részt

MI-összefoglaló

A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.

The trial is looking for adults who got a kidney, liver, or combined liver-kidney transplant and are at high risk of late CMV infection. It tests CytoGam® after preventive antiviral treatment ends.

Életkor
18 to 75 years
Nem
All sexes
A betegség stádiuma
Kidney, liver, or simultaneous liver-kidney transplant recipients at high risk: the donor had CMV antibodies and the recipient did not (D+R-).
Korábbi kezelés
Coming to the end of standard preventive antiviral treatment (valganciclovir prophylaxis). People treated for organ rejection within three months before the end of valganciclovir prophylaxis cannot join.
Biomarker vagy leletérték
Before transplant: donor CMV IgG positive and recipient CMV IgG negative (CMV D+/R-).

A részvétel fő kizáró okai

  • Any other CMV donor/recipient antibody combination than D+/R-
  • Other multi-organ transplants, lung, heart, small bowel or pancreas transplants, or a past bone marrow or stem cell transplant
  • eGFR <30 ml/min/1.73m2, poor transplant organ function, being on dialysis or plasmapheresis, or relisted for transplant
  • Severe reaction to CMV immunoglobulin or other human immunoglobulin, or selective immunoglobulin A deficiency
  • Pregnant or breastfeeding women, or women who can become pregnant and do not use highly effective birth control

Ez a vizsgálat csak szervátültetésen átesett résztvevőket keres. A regiszter mondata, amelyen ez alapul: * High risk pretransplant CMV donor seropositive/recipient seronegative (D+R-) kidney, liver, or simultaneous liver-kidney (SLK) transplant recipients

A regiszter feltételei, szó szerint

Mind a 19 feltétel megnézéseKevesebb

Ki vehet részt

  • High risk pretransplant CMV donor seropositive/recipient seronegative (D+R-) kidney, liver, or simultaneous liver-kidney (SLK) transplant recipients
  • Able to do routine blood testing (normal care for transplant recipients)
  • Written informed consent obtained from the subject before any trial-related procedures
  • Be ≥18 years and ≤75 years of age at time of consent

Ki nem vehet részt

  • Any pre-transplant CMV serologic combinations besides CMV D+/R-
  • Multi organ transplants (other than simultaneous liver-kidney transplant (SLK) recipients) or prior history of bone marrow or stem cell transplant
  • Transplant recipients treated for rejection within three months before the end of valganciclovir prophylaxis
  • Participation in another interventional clinical trial at time of consent or within 30 days prior to study consent
  • Individuals with a history of selective immunoglobulin A deficiency will be excluded, as they may produce antibodies against immunoglobulin A, leading to potential anaphylactic reactions upon receiving blood products containing immunoglobulin A, such as CMV immunoglobulin (e.g. CytoGam® or similar)
  • Women of childbearing potential unless using a highly effective method of contraception during dosing and for 24 weeks after study treatment. Medically acceptable birth control (contraceptives) includes but are not limited to: surgical sterilization (such as hysterectomy or "tubes tied"), approved hormonal contraceptives (such as birth control pills, patch or ring; Depo-Provera, Depo-Lupron, lmplanon), barrier methods (such as condom or diaphragm), an intrauterine device (IUD), abstinence from sex
  • Lung, heart, small bowel, pancreas, or other non-kidney or non-liver transplant recipients
  • Those with a history of severe reaction to CMV immunoglobulin (e.g. CytoGam® or similar) or other human immunoglobulin preparations
  • Any history of acute myocardial infarction (within 12 months of screening), clinically significant arrythmia, or clinically significant ECG abnormality in the opinion of the investigator at time of screening
  • History of active or latent tuberculosis (except those who have completed a documented regimen for latent TB treatment) or severe pulmonary disease [e.g., severe pulmonary hypertension (WHO class IV)] that in the opinion of the investigator that may preclude their ability to safely tolerate study infusions
  • Any history of neurodegenerative disease, including dementia, or stroke with substantial residual disability (modified Rankin score ≥ 3)
  • Any significant history of any treatment nonadherence or any other medical condition that, in the investigator's opinion, would confound the results of the study or put the participant at undue risk
  • Transplant recipients with eGFR <30 ml/min/1.73m2 (as they theoretically could be at higher risk for renal impairment with CMV immunoglobulin), poor transplant organ function (i.e. LFTs > twice the upper limit of normal in liver recipients), or who are on dialysis, or plasmapheresis, or who are relisted for transplant, or who might otherwise at risk of complications at the discretion of the local site investigator
  • Pregnant or nursing (lactating) women confirmed by human chorionic gonadotropin (hCG) laboratory test
  • Subjects who have any of the following laboratory values: eGFR <30 ml/min/1.73m2 ; Hemoglobin <8.0 g/dL; Platelets <50,000 cells/uL; Absolute neutrophil count <1,000 cells/uL; Total bilirubin >2.5 x upper limit of normal; Alanine aminotransferase (ALT) >5 x upper limit of normal; Aspartate aminotransferase (AST)] >5 x upper limit of normal; CMV IgG negative in donor or positive in recipient

A fő feltételek kérdésként

Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.

  • 18 és 75 év között vagy?

Ez a vizsgálat jelenleg itt érhető el: Egyesült Államok.

  • Massachusetts General HospitalBoston, Egyesült ÁllamokContact: MGH Abdominal Transplant UnitRésztvevőt keres
  • University of Texas, SouthwesternDallas, Egyesült ÁllamokContact: Jarrett Hubbard, BARésztvevőt keres

A vizsgálatról

Mit akar kideríteni a vizsgálat

This study is being done to find out if administering CytoGam® after the end of standardly prescribed preventive antiviral treatment can help transplant recipients with a high risk for developing late CMV disease after a liver and/or kidney transplant.

A vizsgálat 2 csoportja

  • Arm A: CytoGam®A vizsgált kezelés

    Participants assigned to receive CytoGam® will receive an infusion once a month for three months at their study site. The infusion will be completed over an average of about 4 hours; these three visits will last about 5 hours. During these study staff will review concomitant medications and adverse events. Participants will be asked to have blood taken at infusion visits and 2 weeks after an infusion visit to check the level of CMV DNA in their blood.

    Kezelés: Cytomegalovirus Immune Globulin Intravenous (Human) monthly for three months

  • Arm B: Standard of CareNincs vizsgálati kezelés, összehasonlításként

    Participants assigned to Arm B, will be asked to complete a telephone call visit once a month. During these visits, a member of study staff will review concomitant medications and adverse events. Participants will be asked to have their blood taken every two weeks to check the level of CMV DNA.

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
Exploratory Use of CMV Immunoglobulin in High Risk (D+R-) Transplant Recipients at the End of Antiviral Prophylaxis to Decrease the Risk of Late CMV Infection
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
Kérdések a feltételekről
Forrás: NCT06958796: ki vehet részt
A regiszteradat frissítve
2025. december 22.